| Study Details | A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa. Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Non-Dialysis (ASCEND-ND) |
| Protocol Number | N/A |
| Phase | III |
| Therapeutic Area | Nephrology |
| Subject Types | With Medical Condition |
| Indication | Anemia |
| Principal Investigator | Dr Titus Lau |
| Investigator Product / Device | Daprodustat |
| Sponsor | GlaxoSmithKline |